Four new SPMS patients not eligible for a Tiziana Life Sciences trial were dosed with foralumab nasal spray in an expanded access program.
Massachusetts General Hospital coordinated the first four platform trials within the HEALEY ALS platform to evaluate ...
Paris, France, February 20, 2025 – EG 427, a biotechnology company leading the development of pinpoint genetic medicines for prevalent chronic diseases in neurology, announced today the successful ...
Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug ...
We recently published a list of 10 Stocks Insiders Spent The Most Money On Recently. In this article, we are going to take a ...
1d
Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for ...
NKGen Biotech (NKGN) announced that Anita Fletcher, M.D. has been appointed as the National Principal Investigator for its Phase 2a clinical ...
Tiziana Life Sciences (TLSA) announced the dosing of an additional four patients in its Intermediate Size Patient Population Expanded Access ...
Rezolute advances therapies for hypoglycemia with RZ358 and RZ402, showing efficacy in trials. Read why RZLT stock is a compelling, albeit cautious, investment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback